Nevirapine Resistance by Timing of HIV Type 1 Infection in Infants Treated with Single‐Dose Nevirapine
Clinical Infectious Diseases2010Vol. 50(10), pp. 1405–1414
Citations Over TimeTop 22% of 2010 papers
Mark A. Micek, Ana Judith Blanco, Ingrid A. Beck, Sandra Dross, Laurinda Matunha, Pablo Montoya, Kristy Seidel, Soren Gantt, Eduardo Matediane, Lilia Jamisse, Stephen Gloyd, Lisa M. Frenkel
Abstract
The detection and persistence of nevirapine-resistant HIV-1 in infants after single-dose nevirapine therapy vary by the timing of infection and the antiretroviral regimen. In infants with persistent high-level nevirapine-resistant HIV-1, nevirapine-based antiretroviral therapy is unlikely to ever be efficacious because of concentrations in long-lived viral reservoirs. However, the absence or decay of nevirapine-resistant HIV-1 in many infants suggests that nevirapine antiretroviral therapy may be effective if testing can identify these individuals.
Related Papers
- → Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in Thailand(2004)461 cited
- → Highly Active Antiretroviral Therapy Versus Zidovudine for Prevention of Mother-to-Child Transmission in a Programmatic Setting, Botswana(2011)19 cited
- → N348I in HIV-1 Reverse Transcriptase Counteracts the Synergy Between Zidovudine and Nevirapine(2012)7 cited
- → Alternating Nevirapine and Zidovudine Treatment of Human Immunodeficiency Virus Type 1-Infected Persons Does Not Prolong Nevirapine Activity(1994)33 cited
- → Newborn treatment with nevirapine plus zidovudine reduces mother-to-child transmission of HIV(2004)2 cited